{
    "clinical_study": {
        "@rank": "126176", 
        "acronym": "ColMetInc", 
        "arm_group": [
            {
                "arm_group_label": "Colesevelam", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Metformin", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Colesevelam + exendin (9-39)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Metformin + exendin (9-39)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo + + exendin (9-39)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Our primary hypothesis is that bile acid sequestrant colesevelam and the antidiabetic drug\n      metformin potentiates the secretion of the gut hormone glucagon-like peptide 1 (GLP-1)."
        }, 
        "brief_title": "The Role of Metformin and Colesevelam in Human GLP-1 Secretion", 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus, Type 2"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Normal hemoglobin\n\n          -  BMI > 23kg/m2\n\n          -  HbA1c <9 %\n\n          -  Informed concent\n\n        Exclusion Criteria:\n\n          -  Liver disease ( aspartate aminotransferase/alanine aminotransferase >2 \u00d7 reference\n             value)\n\n          -  Chronic intestinal disease\n\n          -  History of liver and / or gallbladder disease\n\n          -  Nephropathy (se-creatinine >110 \u00b5M and / or albuminuria)\n\n          -  Insulin or GLP-1-based antidiabetic treatment\n\n          -  History of cholecystectomy or surgical resection of bowel segment\n\n          -  BMI <23kg/m2 or BMI >35 kg/m2\n\n          -  Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02050074", 
            "org_study_id": "H-1-2013-010"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Colesevelam", 
                    "Colesevelam + exendin (9-39)"
                ], 
                "intervention_name": "Colesevelam", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Metformin", 
                    "Metformin + exendin (9-39)"
                ], 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "Placebo + + exendin (9-39)"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Metformin", 
                "Colesevelam"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 29, 2014", 
        "location": {
            "contact": {
                "email": "morten.hansen.02@regionh.dk", 
                "last_name": "Morten Hansen, Dr.", 
                "phone": "+45 3977 2691"
            }, 
            "facility": {
                "address": {
                    "city": "Hellerup", 
                    "country": "Denmark", 
                    "state": "Copenhagen", 
                    "zip": "2900"
                }, 
                "name": "Diabetes Research Division, Department of Medicine, Gentofte Hospital"
            }, 
            "investigator": {
                "last_name": "Morten Hansen, Dr.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "6", 
        "official_title": "The Role of Metformin and Colesevelam in Human GLP-1 Secretion", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: De Videnskabsetiske Komiteer of the Capital Region"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in the gut hormone glucagon-like peptide 1  (GLP-1)", 
            "safety_issue": "No", 
            "time_frame": "0-240 min"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02050074"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital, Gentofte, Copenhagen", 
            "investigator_full_name": "Morten Hansen", 
            "investigator_title": "Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University Hospital, Gentofte, Copenhagen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Gentofte, Copenhagen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}